{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:58:38Z","timestamp":1789577918133,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,28]]},"DOI":"10.7759\/cureus.79831","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T17:18:12Z","timestamp":1740763092000},"source":"Crossref","is-referenced-by-count":1,"title":["Identifying Key Factors Influencing Non-adherence to Imatinib Therapy in Patients With Chronic Myeloid Leukemia"],"prefix":"10.7759","author":[{"given":"Deepak","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeta","family":"Chugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumita","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of Imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus A","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, et al.. Long-term outcomes of Imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017, 376:917-27. 10.1056\/NEJMoa1609324","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens L","year":"2009","unstructured":"Noens L, van Lierde MA, De Bock R, et al.. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009, 113:5401-11. 10.1182\/blood-2008-12-196543","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000818","article-title":"Interventions to improve adherence to tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review","volume":"44","author":"Heiney SP","year":"2021","unstructured":"Heiney SP, Sorrell M, Sheng J, et al.. Interventions to improve adherence to tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review. Am J Clin Oncol. 2021, 44:291-8. 10.1097\/COC.0000000000000818","journal-title":"Am J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23180","article-title":"Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"87","author":"Jabbour EJ","year":"2012","unstructured":"Jabbour EJ, Kantarjian H, Eliasson L, Cornelison AM, Marin D. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol. 2012, 87:687-91. 10.1002\/ajh.23180","journal-title":"Am J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2015.013","article-title":"Factors influencing adherence to imatinib in Indian chronic myeloid leukemia patients: a cross-sectional study","volume":"7","author":"Kapoor J","year":"2015","unstructured":"Kapoor J, Agrawal N, Ahmed R, Sharma SK, Gupta A, Bhurani D. Factors influencing adherence to imatinib in Indian chronic myeloid leukemia patients: a cross-sectional study. Mediterr J Hematol Infect Dis. 2015, 7:e2015013. 10.4084\/MJHID.2015.013","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.2015.002667","article-title":"Chronic myeloid leukemia in India","volume":"3","author":"Ganesan P","year":"2017","unstructured":"Ganesan P, Kumar L. Chronic myeloid leukemia in India. J Glob Oncol. 2017, 3:64-71. 10.1200\/JGO.2015.002667","journal-title":"J Glob Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.02.040","article-title":"Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients with chronic myeloid leukemia receiving imatinib","volume":"16","author":"Unnikrishnan R","year":"2016","unstructured":"Unnikrishnan R, Veeraiah S, Mani S, et al.. Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients with chronic myeloid leukemia receiving imatinib. Clin Lymphoma Myeloma Leuk. 2016, 16:366-371.e3. 10.1016\/j.clml.2016.02.040","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.22541\/au.171834908.81536930\/v1","article-title":"Non-adherence to imatinib despite availability: analysis from a resource limited setting","author":"Pandey D","year":"2024","unstructured":"Pandey D, Chugh PK, Chaudhry S. Non-adherence to imatinib despite availability: analysis from a resource limited setting. Authorea. 2024, 10.22541\/au.171834908.81536930\/v1","journal-title":"Authorea"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V72.1.294.294","article-title":"Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia","volume":"72","author":"Sokal G","year":"1988","unstructured":"Sokal G, Gomez G A, Baccarani M, et al.. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood. 1988, 72:294-8. 10.1182\/blood.V72.1.294.294","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0931-9","article-title":"The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia","volume":"34","author":"Pfirrmann M","year":"2020","unstructured":"Pfirrmann M, Clark RE, Prejzner W, et al.. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020, 34:2138-49. 10.1038\/s41375-020-0931-9","journal-title":"Leukemia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.1188","article-title":"Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ=C30 (+ 3)","volume":"16","author":"Hjermstad MJ","year":"1998","unstructured":"Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ=C30 (+ 3). J Clin Oncol. 1998, 16:1188-96. 10.1200\/JCO.1998.16.3.1188","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour E","year":"2020","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020, 95:691-709. 10.1002\/ajh.25792","journal-title":"Am J Hematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s41999-020-00313-2","article-title":"Medication adherence in the older adults with chronic multimorbidity: a systematic review of qualitative studies on patient's experience","volume":"11","author":"Maffoni M","year":"2020","unstructured":"Maffoni M, Traversoni S, Costa E, Mid\u00e3o L, Kardas P, Kurczewska-Michalak M, Giardini A. Medication adherence in the older adults with chronic multimorbidity: a systematic review of qualitative studies on patient's experience. Eur Geriatr Med. 2020, 11:369-81. 10.1007\/s41999-020-00313-2","journal-title":"Eur Geriatr Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/apjon.apjon_7_17","article-title":"Medication burden of treatment using oral cancer medications","volume":"4","author":"Given BA","year":"2017","unstructured":"Given BA, Given CW, Sikorskii A, Vachon E, Banik A. Medication burden of treatment using oral cancer medications. Asia Pac J Oncol Nurs. 2017, 4:275-82. 10.4103\/apjon.apjon_7_17","journal-title":"Asia Pac J Oncol Nurs"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg L","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005, 353:487-97. 10.1056\/NEJMra050100","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow T","year":"2007","unstructured":"Darkow T, Henk HJ, Thomas SK, et al.. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007, 25:481-96. 10.2165\/00019053-200725060-00004","journal-title":"Pharmacoeconomics"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)72137-9","article-title":"PCN48: Non-adherence to imatinib in chronic myeloid leukemia (CML) patients is associated with short- and long-term negative impacts on health care resource utilization and costs","volume":"13","author":"Guerin A","year":"2010","unstructured":"Guerin A, Bollu V, Guo A, Wu EQ, Yu AP, Sirulnik LA, Griffin JD. PCN48: Non-adherence to imatinib in chronic myeloid leukemia (CML) patients is associated with short- and long-term negative impacts on health care resource utilization and costs. Value Health. 2010, 13:A32. 10.1016\/S1098-3015(10)72137-9","journal-title":"Value Health"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3109\/02813432.2015.1132884","article-title":"Primary adherence to antidepressant prescriptions in primary health care: a population-based study in Sweden","volume":"34","author":"Freccero C","year":"2016","unstructured":"Freccero C, Sundquist K, Sundquist J, Ji J. Primary adherence to antidepressant prescriptions in primary health care: a population-based study in Sweden. Scand J Prim Health Care. 2016, 34:83-8. 10.3109\/02813432.2015.1132884","journal-title":"Scand J Prim Health Care"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4137\/CMO.S32822","article-title":"Is adherence to imatinib mesylate treatment among patients with chronic myeloid leukemia associated with better clinical outcomes in Qatar?","volume":"10","author":"Al-Dewik NI","year":"2016","unstructured":"Al-Dewik NI, Morsi HM, Samara MM, et al.. Is adherence to imatinib mesylate treatment among patients with chronic myeloid leukemia associated with better clinical outcomes in Qatar?. Clin Med Insights Oncol. 2016, 10:95-104. 10.4137\/CMO.S32822","journal-title":"Clin Med Insights Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/306644-identifying-key-factors-influencing-non-adherence-to-imatinib-therapy-in-patients-with-chronic-myeloid-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T17:18:16Z","timestamp":1740763096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/306644-identifying-key-factors-influencing-non-adherence-to-imatinib-therapy-in-patients-with-chronic-myeloid-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.79831","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,28]]}}}